End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse.

Autor: Sarrawi TH; Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan., Zayyat I; Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan., Barakat F; Department of Pathology, King Hussein Cancer Center, Amman, Jordan., Rezeq M; Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan., Jmaian SA; Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan., Madanat F; Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan. Electronic address: Fmadanat@khcc.jo.

Publikováno v: Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2018 Mar; Vol. 11 (1), pp. 41-43. Date of Electronic Publication: 2017 Jun 17.